Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Kew, Kayleigh M ^a   Karner, Charlotta ^b   Mindus, Stephanie M ^c   Ferrara, Giovanni ^c,d,e  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b British Medical Journal Technology Assessment Group   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; LONG ACTING DRUG; SALBUTAMOL; SHORT ACTING DRUG; STEROID; TERBUTALINE; ANTIASTHMATIC AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

AGE DISTRIBUTION; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NONHUMAN; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT PARAMETERS; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; DRUG COMBINATION; FEMALE; MAINTENANCE CHEMOTHERAPY; MALE; META ANALYSIS; METHODOLOGY; NEBULIZER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; NEBULIZERS AND VAPORIZERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897577990     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009019.pub2     Document Type: Review

References (84)

1. Bousquet J, Boulet LP. Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal 2007;30 Suppl 51:358s [P2156].
2. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al.Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respiratory Medicine 2007;101(12):2437-46.
3. Bousquet J, Miravitlles M, Wiren A. Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal 2007;30 Suppl 51:193s [P1185].
4. Cisneros C, Quiralte J, Capel M, Casado MA, Mellstrom C. Cost-effectiveness analysis of budesonide/formoterol in the maintenance treatment and as-needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics 2010;7(4):163-75.
5. Lin Dr J, Chen P, Zhou X, Sun T, Xie C, Xiu Q, et al.Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal 2012;125(17):2994-3001. [0366-6999]
6. NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®, Seretide™ Diskus™ 50/500 μg & Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775]
7. Peters M, Bousquet J. Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal 2007;30 Suppl 51:615s [P3613].
8. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - Cost-effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal 2009;3(3):169-80.
9. AstraZeneca SD. Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 μg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 μg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed, and one inhalation of Symbicort® Turbuhaler® 320/9 μg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled, multi-centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/ (accessed 26 April 2012).
10. Boonsawat W. Cost-effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine 2010;4(4):571-8.
11. Buhl R, Kuna P. Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal 2007;30 Suppl 51:617s [P3620].
12. Kuna P. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged >=16 years with asthma: post hoc analysis of a randomized, double-blind study. Clinical Drug Investigation 2010;30(9):565-79.
13. Kuna P, Peeters M, Buhl R. Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal 2007;30 Suppl 51:357s [P2152].
14. Kuna P, Peters J, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal 2006;28 Suppl 50:205s [P1228].
15. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al.Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice 2007;61(5):725-36.
16. Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology 2008;15(2):e165-76.
17. Price D, Wiren A, Kuna P. Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal 2006;28 Suppl 50:214s [P1274].
18. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology 2007;62(10):1189-98.
19. Tamminen K, Laine J, Soini E, Martikainen J, Kankaanranta H. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion 2008;24(12):3453-61.
20. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - Cost-effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal 2009;3(3):169-80.
21. NCT00259766 . SHARE - Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766]
22. Stallberg B, Ekstrom T, Neij F, Olsson P, Skoogh BE, Wennergren G, et al.A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine 2008;102(10):1360-70.
23. Stallberg B, Lofdahl CG, Skoogh BE, Wennergren G, Olsson P, Neij F, et al.Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin. 2008:[4424].
24. D'Urzo A, Vogeimeier C, Jaspal M, Merino JM, Boulet S. Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:[B35] [Poster: G24].
25. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24(7):695-708.
26. Johansson G, Larsson PER, Andreasson E. Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 432.
27. Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal 2007;14(5):269-75.
28. Vogelmeier C, D'Urzo A. Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 2770.
29. Vogelmeier C, D'Urzo A, Jaspal M, Merino JM, Johansson G, Boulet S. Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20-25; San Diego. 2005:[C33] [Poster: F67].
30. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al.Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal 2005;26(5):819-28.
31. Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged >=16 years) with asthma: a sub-analysis of the COSMOS study. Clinical Drug Investigation 2012;32(7):439-49. [ES:1179-1918: IL:1173-2563]
32. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - Cost-effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal 2009;3(3):169-80.
33. AstraZeneca . Symbicort single inhaler therapy for asthma in a general practice setting. www.clinicaltrials.gov (accessed 24 April 2012).
34. AstraZeneca . SALTO - Symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov (accessed 24 April 2012).
35. Atienza T, Aquino T, Fernández M, Boonsawat W, Kawai M, Kudo T, Ekelund J, Ivanov S, Carlsson LG. Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results. Respirology 2013;18(2):354-63.
36. Balanzat A, Centanni S, Palmqvist M, Rabe K. Budesonide/formoterol single inhaler therapy reduces over reliance on rapid acting reliever medication [Abstract]. European Respiratory Journal 2004;24 Suppl 48:344s.
37. NCT00839800 . Study to Investigate the Efficacy of Symbicort SMART. (SAKURA). www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D589LC00001; clinicaltrials.gov study ID: NCT00839800]
38. Ghosh CS, Ravindran P, Joshi M, Nair SM. Cost effectiveness of preventer-reliever combination in the management of chronic asthma - RCT. Journal of Clinical Epidemiology 1998;51 Suppl 1:32S.
39. Haughney J, Aubier M, Buhl R, Ekstrom T, Ostinelli J, van Schayck CP, et al.Patient characteristics to determine an appropriate maintenance dose of budesonide/formoterol maintenance and reliever therapy [Abstract]. European Respiratory Society Annual Congress; 2009 Sept 12-16; Vienna. 2009:[3051].
40. Haughney J, van Schayck OCP, Aubier M, Ostinelli J, Ekström T, Jörgensen L, et al.Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients [Abstract]. European Respiratory Society Annual Congress; 2010 Sept 18-22; Barcelona. 2010:[P1212].
41. Loukides S, Papageorgiou M, Karokis A, Zervas E, Christodoulopoulou A, Papageorgiou N, et al.Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FUM) is effective in asthma control [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 848.
42. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al.Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Current Medical Research and Opinion 2006;22(5):809-21.
43. Bateman ED, Palmqvist M, Juniper EF, Zhu Y, Ekstrom T. Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed-dose budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004:A37 Poster J75.
44. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 1060.
45. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006;130(6):1733-43.
46. Bruce SA, Scherer YK. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence-Based Nursing 2005;8(3):78.
47. O'Byrne PM. Acute asthma intervention: Insights from the STAY study. Journal of Allergy & Clinical Immunology 2007;119(6):1332-6.
48. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al.Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory & Critical Care Medicine 2005;171(2):129-36.
49. O'Byrne PM, Godard P, Pistolesi M, Ekstrom T. Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004:A37 Poster J93.
50. Pistolesi M, Godard P, Albers R, Ekstrom T. Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma [Abstract]. European Respiratory Journal 2004;24 Suppl 48:509s.
51. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - Cost-effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal 2009;3(3):169-80.
52. AstraZeneca SD. Efficacy of Symbicort® Turbuhaler® 160/4.5 ìg as needed versus Oxis® 4.5 ìg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 ìg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study. www.astrazenecaclinicaltrials.com/ (accessed 24 April 2012).
53. Pistolesi M, Godard P, Albers R, Ekstrom T. Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma [Abstract]. European Respiratory Journal 2004;24 Suppl 48:509s.
54. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.[see comment]. Lancet 2006;368(9537):744-53.
55. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark - Cost-effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal 2009;3(3):169-80.
56. Riemersma RA, Postma DS, van der Molen T. Budesonide/formoterol maintenance and reliever therapy for asthma in general practice [Abstract]. American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A612[#A29].
57. Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
58. Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis. Monaldi Archives for Chest Disease 2009;71(4):161-9. [1122-0643: (Print)]
59. Barnes PJ. Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. British Medical Journal 2007;335(7618):513.
60. Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, et al.Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. http://respiratory-research.com/content/12/1/38 (accessed 7 December 2013). [DOI: 10.1186/1465-9921-12-38]
61. Bisgaard H. Effect of long-acting Beta2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology 2003;36(5):391-8.
62. British Thoracic Society/ Scottish Intercolleate Guideline Network. British Guidelines on the Management of Asthma [revised January 2012]. http://www.sign.ac.uk/ (accessed 5 September 2012).
63. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2]
64. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
65. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007085.pub2]
66. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007313.pub2]
67. Cates Christopher J, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3;: CD007313]
68. Czarnecka K, Chapman KR. The clinical impact of single inhaler therapy in asthma. Clinical and Experimental Allergy 2012;42(7):1006-13. [1365-2222: (Electronic)]
69. Delea TE, Hagiwara M, Stanford RH, Stempel DA. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clinical Therapeutics 2008;30(3):560-71.
70. Edwards SJ, von Maltzahn R, Naya IP, Harrison T. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. International Journal of Clinical Practice 2010;64(5):619-27. [1742-1241: (Electronic)]
71. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59(7):550-6.
72. GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013).
73. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, et al.Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533]
74. Harrison T, Oborne J, Newton S, Tattersfield A. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363(9405):271-5.
75. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
76. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. www.cochrane-handbook.org, 2011.
77. Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD004106.pub4]
78. Lipworth BJ, Jackson C. A SMART choice for primary care asthma therapy?. http://www.bmj.com/cgi/eletters/335/7618/513#178078 (accessed 13 October 2007).
79. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al.Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005535]
80. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulmonary Pharmacology and Therapeutics 2001;14(1):29-34.
81. The Nordic Cochrane Centre; Cochrane Collaboration. Review Manager (RevMan) Version 5. Copenhagen: The Nordic Cochrane Centre; Cochrane Collaboration, 2008.
82. Song F, Parekh S, Hooper L, Loke Y, Ryder J, Sutton A, et al.Dissemination and publication of research findings: an updated review of related biases. http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDYQFjAA&url=http%3A%2F%2Fwww.hta.ac.uk%2Ffullmono%2Fmon1408.pdf&ei=f9TfUdf-C6_T7AbRjICoDg&usg=AFQjCNHXDsDiIJivPVumE_aFvjnvjMhqUw&sig2=bouiXecktYUZw-SPeLE22w&bvm=bv.48705608, d.ZGU&cad=rja (accessed 7 December 2013). [DOI: 10.3310/hta14080]
83. Sovani MP, Whale CI, Oborne J, Cooper S, Mortimer K, Ekström T, et al.Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice 2008;58(546):37-43.
84. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2]